JP2021531314A5 - - Google Patents
Info
- Publication number
- JP2021531314A5 JP2021531314A5 JP2021504283A JP2021504283A JP2021531314A5 JP 2021531314 A5 JP2021531314 A5 JP 2021531314A5 JP 2021504283 A JP2021504283 A JP 2021504283A JP 2021504283 A JP2021504283 A JP 2021504283A JP 2021531314 A5 JP2021531314 A5 JP 2021531314A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- alkyl
- group
- pharmaceutically acceptable
- solvate
- Prior art date
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862711273P | 2018-07-27 | 2018-07-27 | |
| US62/711,273 | 2018-07-27 | ||
| PCT/US2019/043608 WO2020023846A1 (en) | 2018-07-27 | 2019-07-26 | Pyridone a2r antagonists |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021531314A JP2021531314A (ja) | 2021-11-18 |
| JPWO2020023846A5 JPWO2020023846A5 (https=) | 2022-08-01 |
| JP2021531314A5 true JP2021531314A5 (https=) | 2022-08-01 |
| JP7394831B2 JP7394831B2 (ja) | 2023-12-08 |
Family
ID=69182367
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021504283A Active JP7394831B2 (ja) | 2018-07-27 | 2019-07-26 | ピリドンａ２ｒアンタゴニスト |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US12064433B2 (https=) |
| EP (1) | EP3829581B1 (https=) |
| JP (1) | JP7394831B2 (https=) |
| KR (1) | KR102809468B1 (https=) |
| CN (1) | CN112996509B (https=) |
| AU (1) | AU2019312296B2 (https=) |
| CA (1) | CA3107079A1 (https=) |
| ES (1) | ES2982326T3 (https=) |
| PL (1) | PL3829581T3 (https=) |
| WO (1) | WO2020023846A1 (https=) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020185859A1 (en) | 2019-03-12 | 2020-09-17 | Arcus Biosciences, Inc. | Treatment of oncogene-driven cancers |
| US12310965B2 (en) | 2019-03-29 | 2025-05-27 | Arcus Biosciences, Inc. | Treatment of cancer utilizing an identified adenosine fingerprint |
| CN115298165B (zh) | 2020-03-19 | 2024-09-17 | 艾库斯生物科学有限公司 | 作为HIF-2α抑制剂的四氢化萘和四氢喹啉化合物 |
| JP2021183587A (ja) * | 2020-05-22 | 2021-12-02 | 武田薬品工業株式会社 | 複素環化合物 |
| AU2021292195A1 (en) | 2020-06-17 | 2023-01-05 | Arcus Biosciences, Inc. | Crystalline forms of a CD73 inhibitor and uses thereof |
| KR20230062845A (ko) | 2020-09-03 | 2023-05-09 | 이뮨센서 테라퓨틱스, 인코포레이티드 | 퀴놀린 cgas 길항제 화합물 |
| JP2024506858A (ja) | 2021-02-02 | 2024-02-15 | リミナル・バイオサイエンシーズ・リミテッド | Ｇｐｒ８４アンタゴニストおよびその使用 |
| CN117295741A (zh) | 2021-05-21 | 2023-12-26 | 艾库斯生物科学有限公司 | Axl化合物 |
| JP2024521712A (ja) | 2021-05-21 | 2024-06-04 | アーカス バイオサイエンシーズ，インコーポレーテッド | Ａｘｌ阻害化合物 |
| WO2023077046A1 (en) | 2021-10-29 | 2023-05-04 | Arcus Biosciences, Inc. | Inhibitors of hif-2alpha and methods of use thereof |
| CN119137112A (zh) | 2022-03-02 | 2024-12-13 | 免疫传感器治疗股份有限公司 | 喹啉cGAS拮抗剂化合物 |
| CA3256561A1 (en) | 2022-05-02 | 2023-11-09 | Arcus Biosciences, Inc. | Anti-tigit antibodies and their uses |
| EP4554680A1 (en) | 2022-07-15 | 2025-05-21 | Arcus Biosciences, Inc. | Inhibitors of hpk1 and methods of use thereof |
| US20260028336A1 (en) | 2022-07-20 | 2026-01-29 | Arcus Biosciences, Inc. | Cbl-b inhibitors and methods of use thereof |
| WO2024081385A1 (en) | 2022-10-14 | 2024-04-18 | Arcus Biosciences, Inc. | Hpk1 inhibitors and methods of use thereof |
| EP4604920A1 (en) | 2022-10-20 | 2025-08-27 | Arcus Biosciences, Inc. | Lyophilized formulations of cd73 compounds |
| WO2024097736A1 (en) | 2022-11-02 | 2024-05-10 | Arcus Biosciences, Inc. | Processes for preparing azolopyrimidine compounds |
| EP4705292A1 (en) | 2023-05-05 | 2026-03-11 | Arcus Biosciences, Inc. | Cbl-b inhibitors and methods of use thereof |
| US20250011318A1 (en) | 2023-05-25 | 2025-01-09 | Arcus Biosciences, Inc. | Cbl-b inhibitors and methods of use thereof |
| WO2025054339A1 (en) | 2023-09-08 | 2025-03-13 | Arcus Biosciences, Inc. | Triazolopyridine compounds as inhibitors of kit |
| WO2025072330A1 (en) | 2023-09-26 | 2025-04-03 | Arcus Biosciences, Inc. | Kit inhibitor compounds and methods of use thereof |
| WO2025076299A1 (en) | 2023-10-06 | 2025-04-10 | Arcus Biosciences, Inc. | Cbl-b inhibitors and methods of use thereof |
| TW202523302A (zh) | 2023-11-02 | 2025-06-16 | 美商阿克思生物科學有限公司 | 噻唑化合物及其使用方法 |
| WO2026006759A1 (en) | 2024-06-28 | 2026-01-02 | Arcus Biosciences, Inc. | Pharmaceutical compositions, dosage forms, and methods of making and using same |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7674791B2 (en) | 2003-04-09 | 2010-03-09 | Biogen Idec Ma Inc. | Triazolopyrazines and methods of making and using the same |
| TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
| WO2006091898A2 (en) * | 2005-02-25 | 2006-08-31 | Adenosine Therapeutics, Llc | Pyrazolyl substituted xanthines |
| AU2006230099B2 (en) | 2005-03-25 | 2012-04-19 | Gitr, Inc. | GITR binding molecules and uses therefor |
| AU2007227021B2 (en) * | 2006-03-17 | 2012-12-20 | Gilead Sciences, Inc. | Method of preventing and treating hepatic disease using A2B adenosine receptor antagonists |
| EP2166854A4 (en) | 2007-06-13 | 2012-05-16 | Merck Sharp & Dohme | TRIAZONE DERIVATIVES FOR THE TREATMENT OF MORBUS ALZHEIMER AND RELATED SUFFERINGS |
| ES2776406T3 (es) | 2007-07-12 | 2020-07-30 | Gitr Inc | Terapias de combinación que emplean moléculas de enlazamiento a GITR |
| EP2473531A4 (en) | 2009-09-03 | 2013-05-01 | Merck Sharp & Dohme | Anti-gitr antibodies |
| JP5998060B2 (ja) | 2010-03-04 | 2016-09-28 | マクロジェニクス，インコーポレーテッド | Ｂ７−ｈ３と反応性のある抗体、その免疫学的に活性なフラグメントおよびその使用 |
| PT2614082T (pt) | 2010-09-09 | 2018-12-03 | Pfizer | Moléculas de ligação a 4-1bb |
| WO2013130811A1 (en) | 2012-02-29 | 2013-09-06 | Chemocentryx, Inc. | Pyrazol-1-yl benzene sulfonamides as ccr9 antagonists |
| JP6378759B2 (ja) | 2013-07-02 | 2018-08-22 | ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | Ｓｕｍｏ活性化酵素阻害剤として有用なヘテロアリール化合物 |
| US10138212B2 (en) * | 2015-02-06 | 2018-11-27 | Merck Sharp & Dohme Corp. | Aminoquinazoline compounds as A2A antagonist |
| CA3158951A1 (en) | 2016-08-15 | 2018-02-22 | Purdue Research Foundation | 4-substituted aminoisoquinoline derivatives |
| CN110214012B (zh) * | 2017-01-20 | 2023-05-09 | 艾库斯生物科学有限公司 | 用于治疗癌症相关疾病的唑嘧啶 |
-
2019
- 2019-07-26 US US17/263,016 patent/US12064433B2/en active Active
- 2019-07-26 AU AU2019312296A patent/AU2019312296B2/en active Active
- 2019-07-26 KR KR1020217005878A patent/KR102809468B1/ko active Active
- 2019-07-26 EP EP19841391.6A patent/EP3829581B1/en active Active
- 2019-07-26 JP JP2021504283A patent/JP7394831B2/ja active Active
- 2019-07-26 WO PCT/US2019/043608 patent/WO2020023846A1/en not_active Ceased
- 2019-07-26 CN CN201980064256.XA patent/CN112996509B/zh active Active
- 2019-07-26 PL PL19841391.6T patent/PL3829581T3/pl unknown
- 2019-07-26 ES ES19841391T patent/ES2982326T3/es active Active
- 2019-07-26 CA CA3107079A patent/CA3107079A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021531314A5 (https=) | ||
| JPWO2020023846A5 (https=) | ||
| JP2020111618A5 (https=) | ||
| JP2019529500A5 (https=) | ||
| JPWO2018204661A5 (https=) | ||
| HRP20231157T1 (hr) | Azolopirimidin za liječenje poremećaja povezanih s rakom | |
| JP2017538678A5 (https=) | ||
| JP5881705B2 (ja) | Ｎａｍｐｔの阻害のための新規化合物及び組成物 | |
| JP2019501223A5 (https=) | ||
| JP2019535720A5 (https=) | ||
| JPWO2018213377A5 (https=) | ||
| JP2021516237A5 (https=) | ||
| JP2017525753A5 (https=) | ||
| JP6559785B2 (ja) | Ｅｇｆｒ及びｐｉ３ｋの小分子阻害剤 | |
| HRP20171248T1 (hr) | Amino-supstituirani imidazopiridazini | |
| AU2010290199B2 (en) | Kinase inhibitors, prodrug forms thereof and their use in therapy | |
| JP2017538677A5 (https=) | ||
| IL276813B2 (en) | 4-SUBSTITUTED-5-AMINO-OCTAHYDROCYCLOPENTA[c]PYRROLE-5-CARBOXYLIC ACID DERIVATIVES, PHARMACEUTICAL COMBINATIONS THEREOF AND USE THEREOF IN TREATMENT OF DISEASES | |
| JP2018525441A5 (https=) | ||
| CN110573500A (zh) | N-(氮杂芳基)环内酰胺-1-甲酰胺衍生物及其制备方法和应用 | |
| JP2014521625A5 (https=) | ||
| JP2016538344A5 (https=) | ||
| JP2011527692A5 (https=) | ||
| RU2016134749A (ru) | Гетероциклическое сульфонамидное производное и лекарственное средство, содержащее такое производное | |
| JPWO2020247496A5 (https=) |